secwatch.observer — SEC 8-K summary
======================================

Issuer:     USBC, Inc. (USBC)
CIK:        0001074828
Form:       8-K
Filed at:   2023-08-18T23:59:59+00:00
Accession:  0001654954-23-010993
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Know Labs Q3 net loss $3.59M, EPS loss $0.07, cash $3.93M, expects to fund through Dec 2023
--------------------------------------------------------------------------------

- Net loss of $3.59M in Q3 FY2023 vs $3.03M year ago; EPS loss $0.07 unchanged.
- Cash dropped to $3.93M from $12.59M at Sept 30, 2022; net cash used in ops $8.97M in 9 months.
- R&D expense rose to $1.87M from $1.27M YoY on Gen1 device development; SG&A fell to $1.35M.
- Completed Gen1 non-invasive glucose monitor on June 7, 2023; path to FDA trials and commercialization.
- Company expects to raise additional funds via preferred stock, convertible debentures, and equity in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1074828/000165495423010993/0001654954-23-010993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1074828/000165495423010993/know_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer